Link Between GLP-1 Weight Loss Drugs and Nail Issues
It has been reported that GLP-1 medications used in the treatment of obesity and type 2 diabetes may be associated with dermatological problems such as nail splitting and discoloration.
A new study on GLP-1 medications widely used in the treatment of obesity and type 2 diabetes has revealed that issues such as nail splitting and discoloration are observed at higher rates in individuals using these drugs.
Data from Four Countries Examined
The results of the study, which examined data from a total of 1,904 individuals from France, the USA, Brazil, and Mexico, were shared with the public at the European Academy of Dermatology and Venereology Congress held in Vienna.
In the study, 39 percent of GLP-1 users stated that they experienced nail splitting, while this rate was determined to be 9 percent in the comparison group that never used the medications.
Nail and Discoloration Findings
According to EADV data, 66 percent of individuals using GLP-1 stated that they experienced at least one nail disorder, whereas this rate remained at 53 percent in the comparison group.
While complaints of nail discoloration were observed at a rate of 46 percent among GLP-1 users, this rate was recorded as 17 percent in the control group.
Experts Emphasize Direct Cause
Charles Taieb, the author of the study, emphasized that the obtained results point to a clear relationship between the two groups, but not every symptom that arises during the treatment process can be directly attributed to the drug.
The condition of the nail plate separating from the nail bed, medically referred to as onycholysis, can also be triggered by different factors such as injuries, skin diseases, infections, and nutritional deficiencies.
Hair and Scalp Complaints Evaluated
In a separate study conducted on the same participant group, hair and scalp complaints were addressed in detail, and 50 percent of GLP-1 users reported unusual hair loss.
Among drug users, the proportion of those reporting a decrease in hair volume or density was 42 percent, while in the comparison group, this rate was recorded as 19 percent.
Limitations of the Study
It was noted that the participants of the study reported their symptoms themselves and that the individuals were not followed with regular dermatological examinations starting prior to treatment.
While details of the medications used were not shared in the congress announcement, it was stated that the nail study was conducted with the institutional support of DUCRAY Laboratories.